Specialty drugs are expensive because they’re biologically complex to make, costly to develop, often face little market competition, and move through a pricing system that rewards high list prices. In 2019, the average specialty brand-name drug cost $4,260 per prescription, compared to $179 for a nonspecialty brand-name drug. That gap has been widening: specialty drug prices grew at 13.2% per year from 2010 to 2019, while nonspecialty drugs grew at just 2.6%. Specialty medications now account for over half of all U.S. drug spending despite being used by a small fraction of patients.
They’re Built in Living Cells, Not Mixed in a Lab
Most traditional drugs are small molecules made through chemical synthesis. You combine known chemicals in predictable reactions, and the result is a stable, reproducible pill. Specialty drugs, particularly biologics, work differently. They’re large, complex proteins manufactured inside living cells, most commonly a line of Chinese hamster ovary (CHO) cells used to produce over 70% of approved recombinant protein therapies.
These cells must be grown in suspension cultures using precisely defined, serum-free media to ensure consistency across batches. The proteins they produce need specific modifications (like the addition of sugar molecules) to function correctly in the human body. CHO cells can’t always perform these modifications the way human cells do, and some of the sugar structures they produce can trigger immune reactions in patients. That means manufacturers must screen large numbers of cell clones to find ones that produce safe, effective protein, discarding otherwise productive lines that fail quality checks.
This biological variability is the core reason manufacturing costs are so high. A traditional drug factory runs chemical reactions. A biologic factory maintains living organisms under tightly controlled conditions, then extracts, purifies, and tests the proteins they secrete. Every batch requires extensive quality verification that simply isn’t necessary for conventional pills.
Development Costs and the Price of Failure
Bringing any new drug to market is expensive, but the full picture is worse than the headline numbers suggest. A 2024 analysis in JAMA Network Open estimated the mean cost of developing a single new drug at roughly $173 million. That figure, though, only covers successful drugs. When you factor in the cost of all the candidates that failed during development (and most do fail), the expected cost per approval rises to about $516 million. Add in the cost of capital, the money tied up for years during clinical trials that could have been invested elsewhere, and the total climbs to roughly $879 million per approved drug.
Specialty drugs often sit at the higher end of this range. They treat complex diseases, require longer and more complicated clinical trials, and demand extensive post-marketing safety monitoring. Manufacturers price these drugs to recoup not just the cost of the one that succeeded, but the many that didn’t.
Small Patient Populations, Limited Competition
Many specialty drugs treat rare or serious conditions with small patient populations. The Orphan Drug Act, passed in 1983, was designed to make developing these drugs financially viable by offering manufacturers seven years of exclusive marketing rights. During that period, the FDA cannot approve a generic or another version of the same drug for the same condition. Manufacturers also receive tax incentives, research grants, fee waivers, and help with study design.
These incentives have successfully spurred development of treatments for rare diseases that would otherwise have been ignored. But they also create conditions where a single company controls the only available treatment, with no competitive pressure to lower prices. Even after the exclusivity window closes, the complexity of biologics means generic alternatives (called biosimilars) are far harder to bring to market than traditional generics. You can’t simply copy a molecule made by living cells the way you can replicate a chemical formula.
Biosimilars do eventually provide relief. When they enter the market, their sales price averages about 50% less than the original biologic’s price at launch. But the path to approval is slower and more expensive than for traditional generics, so fewer competitors enter and price drops take longer to materialize.
Cold Chains, Special Handling, and Monitoring
Specialty drugs rarely sit on a regular pharmacy shelf. Many require refrigeration throughout their entire journey from manufacturer to patient, a process called cold-chain distribution. This means temperature-monitoring devices in every shipment, insulated packaging, signature-required deliveries, and liability costs when something goes wrong. A shipment that arrives too warm may need to be discarded entirely.
Beyond logistics, many specialty drugs require intensive clinical support. Some carry FDA-mandated safety programs that require lab tests before each dose can be dispensed. Pharmacists track patient adherence, monitor for side effects, and provide extended counseling that goes well beyond handing over a pill bottle. These services add real costs at every step of the supply chain.
The Rebate System Inflates List Prices
The way specialty drugs are priced involves a layer of complexity most patients never see. Pharmacy benefit managers (PBMs) negotiate rebates from manufacturers on behalf of insurance plans. This creates two competing pricing strategies: a manufacturer can set a low list price with a small rebate, or a high list price with a large rebate. Both can result in a similar net cost to the insurer after rebates are applied.
The problem is that high list prices with large rebates have become the dominant approach. PBMs prefer it because larger rebates look like bigger savings. Manufacturers accept it because it’s become the cost of getting their drug on an insurer’s approved list. But patients often pay cost-sharing amounts (copays or coinsurance) based on the high list price, not the lower net price that insurers actually pay after rebates. The rebate dollars flow between manufacturers, PBMs, and insurers, while patients face the sticker price.
What This Means for Patients
High prices translate directly into people not filling their prescriptions. Research consistently shows a steep relationship between out-of-pocket costs and what’s called prescription abandonment, where a patient gets a prescription but never picks it up. When cost sharing stays below $50, abandonment rates for specialty drugs hover between 1.3% and 10%. Once costs cross $100, abandonment jumps to between 32% and 75%, depending on the drug and condition. Patients facing costs above $500 are four times more likely to abandon their prescriptions than those paying $100 or less.
For some conditions, the consequences are stark. Among patients prescribed biologic treatments for multiple sclerosis, more than one in four abandoned their prescriptions when cost sharing exceeded $200. For rheumatoid arthritis biologics, abandonment reached nearly 33% in the highest cost-sharing group. These aren’t optional medications. They treat progressive diseases that worsen without treatment.
The median out-of-pocket cost for specialty drugs is around $25, which sounds manageable. But that median masks wide variation. At the 95th percentile, patients pay $122 or more per fill, and many specialty drugs require monthly refills indefinitely. The cumulative annual burden pushes many patients past the threshold where they simply stop treatment.
Why Prices Keep Rising
No single factor explains specialty drug pricing. It’s the compounding effect of all these forces acting together. Genuine manufacturing complexity and high development costs create a baseline that’s far above traditional drugs. Limited competition, reinforced by patent protections and the biological difficulty of making biosimilars, removes the market pressure that drives down prices in other drug categories. The rebate system creates incentives to set list prices high. And the diseases these drugs treat are serious enough that patients and doctors have little choice but to accept whatever price is set.
Specialty drugs will account for over half of all U.S. drug spending in 2025 and beyond, a share that continues to grow. The pipeline of new drugs in development is increasingly dominated by biologics and other specialty therapies, meaning the cost pressures are structural, not temporary. Biosimilar competition will chip away at prices for older drugs, but new specialty launches consistently enter the market at higher price points than the therapies they replace.